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PROPOSAL TOR COUNCTL DECISION AND AI{NEX
FINAI{CTAL RECORD
IMPACT ON SI,I.ALL AND II{EDIUM-SIZED ENTERPRISES
SUUI{ARY
Infectious disease is no longer the maJor cause of illness ordeath in the western world. Inetead, muCh disease has a ge,netic
component : it may be the result of inheritance of a sinEledefectiv_e gene (monof actorial ) or of the interaction of nul uifilegene defects (multifactorial) with environmental factore. Many
conmon and detrilitating diseases such as coronary artery disraseldiabetes and the maJor psychoses, faLl into the latter s6!a,]o3tri.e. the disease results from the exposure of genetilaliy
susceptible people to environmental fact,ois. predictive MedLcin6seekstopredictsusceptibi1itytodiseaseswffi:he,irprevention ang early diagnosis, as welr as to improved prog:rosis
and, eventually, treatment.
Tl. human genome is the complete set of genetic material(deoxyribonucleic acidr or DNA)- which embodies ihe instrucr:ionsdescribing each human being. rt is novr possible to analyser, oiTapr the genome in such a way that one can ',read',- r:ireseinstructions and, in so doing, locate the genes ,oti"n, whenalteredr-_give rise- to particulal diseases. Aroirg the way it wil_rbe possible to make fundamental nerr discoveries in bi6logy 
""aacqui-re new technology for medicine.
The Predictive Medj-cine Programme will contain the follgwingstrands 3
- improvement of the resolution of the human Eenetic sdp, i-.e.creation of- nap of !l,e human genome, consisting -of DNAmarkers, whi-ch isould enabLe researcliers td locate genes ee rsilyand quickly;
the settS-nE up of ordered crone libraries, i. e. rofcollections of ordered sets of DNA fragments Irni"n f :uf iyrepresent the DNA present in the entir6 genome, sele ,cte&chromosomes or chromosomal fragments;
the improvement of advanced genetic technologies and, thlougha training progranme, the spreading of these advancedtechnologies throughout the Menb6r States.
rl"- 
-programme is ? European response to the internationalchallenges prese_nted by tne largi-scale urorogiE;r researchproJects in the united states ruapping and seque;cing the uumanGenome) and Japan (Human Frontief-science progranme). Althoughit- is a. programme of basi_c precompetitive ,"i"ai.-rr, both newinformation and new materials -of potlntiat commercial value willresurti new t_e-chnological processes will also be aevetopea.These wirl al"l contribute- to the development of nuroie;;sbiotechnology i-ndrrstry often based in small and medium-sizedenterprises.
1 th-'.
a,
.." e$.{.,'
As the title implies, the content of the programme wirl have theurtimate aim of 
-identifying genes invorved -in disease, with aview to their isolation and gtiuctural analyeis.
The enor:nous increase in genetic information 
- or rather the usesto which it may_be put does raise ethical questions. Aspectssuch as personal privacy must be weighed agafnst general h6althcare considerations; the ability to diagnose diseaie will outrunthe possibilities of treating it. These and many other issues
must be given serious consideration.
RESEARCH PROGRAMME rN THE FIELD OF HEALTH : PREDTCTM MEDI:CINE-
HUMAN GENO}IE AT.TAIYSIS
1. REASONS T'OR PROPOSAL
1.1 WHAT IS PREDICTIVE MEDICINE?
Fifty years ago the principal cause of morbidity and mortaritywas infectious disease but ;ith the discovery of antibiotics, andirnprovements 
-il lyeiene and pest control, ii is now a minor onein industrialized countries. Apart from the 
"orr"eqo"ncos ofaccident or ttarr much disease- todiy has a genetic component, wh:Lchmay be of greater or lesser importince. dver ttre pi'it few yearsa great deal has been learned lbout those diEeases which are dueto the inheritance of a silgIe defective ger,er-lnougn in mostcases rre are sti}I very far from a remedy,
However, when it comes to the conrmon diseases such as coronaryartery disease, diabetes, cancer, autoimrnune diseases, the ma-ioipsychoses and- other important diseases of western society, theposition is far less clear. These conditions have a st,rongenvironrnental c,omponent qnd arthough genetic factors areundoubtedly involved, they do not forlo'w any clear-cut pattern ofinheri-tance- put anoth6r way, the disease resurts fronr theexposure of Eenetically susceptibre individuats ;t;;;"lations toenvi-i:onmental causes; prevention wiLl. deperrd or, - i'"aocing thelevels gf- exposure eithler 
- 
in. pofurations 9r, inore probabrlr, insusceptibie individuals' As i[ Ls most unlikeiy lrt"i we wilr beable to remove cornpletely the environrnlntar ri.ir factors, :Lt isimportant that we learn ai much." po"*ibre alrout trr* genetir:alry$etgnyine$ predisposing factors aha helce identify high_riskindividuars. rn summar{t, Predictive Medicine seeks- to pr'tectindividuals from the -kinas of iirnesses to which they aregenetically most vulnerable and, where appropriate, to preventthe transmission of the genetic susceptLbilities to the nextgeneration.
L.2 SCIENTTFIC BASIS FOR PREDICTTVE UEDTCINE
L.2.L THE ORGANTZATTON OF GENETIC TNFORI{ATTON:
U.APPTNG HUUAN GENES
The human qenome is the complete set of genetic mate'ia.l-deoxyribonuc-reic 
..ia ii-l,ial -which embodies the instruct ionsdescribing each human being. rt is now within the rearm* ofpoesibility to "read" these instructiorr" Ln their entirety an<i,in doing so, to make fundamental new discoveries inbiology, to rearn to predict ana -uitimately treat geneti-cdiseases, and to acquire ier technoroqy---o" medicine.
Each human being has two sets of 2g chromosomes along which arearranqed an unknown number of genes G--""q,r"rr"" of bases in DNAwhich codes for one protein), tf,e best tot"t estimate of which i-s50'000 to 100'000. Each gene is composed of DNA, which i.s a
thread-rike gubstance made up of nucleotides (a purlne orpyrimidine baee attached to a sugar and phosphate gfoup), andgenerally found as two strands wrapped around each other in theforrn of a doubre helix. The two strands are held together bybonds between base pairs of nucleotides. The linear pittern oi
nucleotides in the genome is known as the DNA sequen-e and itslength ie measured in base pairs of DNA. The- human genome
contains about 3r000 million base pairs.
A variation in this hereditary set of instructions occurs whenthere is a mutationr or change in the sequence or number of
nucleotides in one or more genes. The challenge is to find thegenes which, having mutated, give rise to a particular disease.Logically, this must be achieved by first Iocating the position
of the gienes along the chromosomes and then - defining thesequence of nucreotides that determine normar genetic
characteristics; only by defining the normal genetic gtructure
can the abnormal then be recognized. such a genetic map is the
equivalent of a dictionary since it provides a unique ordering ofthe genes. we need onry think of the probrem of looking up a
word without a dictionary or of finding a book in a tiurary
without a catarogue. Having acceas to this "human genedictionary" is thus absolutely fundamental to the speed with
which we can analyse human genetic variation and to our
understanding of the complex ways in which genes interrelate todetermine human development.
L.2.2 THE OCCURRENCE OF GENETIC DTSEASE
Genetic variation giving rise to disease can be present in allbody cerrs, incruding the germ (egg and sperm) cells, and can betransmitted from one generation to the next. Other variation ispresent only in somatic (non-sexual) cells and has conseguences
only for that person. Many tlpes of cancer arise as a result of
mutations of the latter t1pe.
In broad terms, disease involving inherited genetic factors canbe divided into three categories 3
eingle gene defects (monofactorial) which show simpleMendelian inheritance patterns. Most of these conditions ire
rare in themselves but since there are many of them, they
represent in total a substantial burden of disease. Currently
some 4t200 single gene defects are recognized and manifest in2.5t of all liveborn in Western European populations;
multiple gene defects (multifactorial), in which multiplegenetic and environmental factors are involved. Many conmondebilitating diseases fall into thiE category;
- abnormalities of chromosome number and structure, as in Down's
slmdrome.
The incidence of some diseases whichdefects is given in Table 1; that of
multifactorial origin is in Table 2.
are due togome conmon single genediseases of
Table 1 : occurrence of some single gene defect diseasea in
Europe
Disease Occurrence related to
number of births Prognosis
Cystic fibrosis
Sickle cell disease
Phenylketonuria
Lesch-Nyhan Slmdrome
Beta-thalaseemia
Duchenne muscular
dystrophy
Immunodeficiencies
L/2 t500
1/6 r 000't
L/L5,000
L/L6 r 000
**
L/7 r000*t'*
tife rarely
exceeds 20 yearsVariable serious-
ness, of ten lethalL
Favourable if earJ-y
diagnosis
Kidney and brain
disturbance,generally lethalLife rarely exceeds
20 years
Myopathy after bhethe age of four,fatal outcome
around 20 years
High death rate****
* rnfrequent in Europeans, sickle celr disease (a haemorytic
anaemial nay have a frequency exceeding L/Loo in some A?ric:rnpopulations' L/400 in Caribbean islanders and L/2|,OO in blirckAmericans.
-** 
Infrequent in Northern Europe, beta-thalassaemia (ano.Eherhaemolytic anaemia) is widespread in the Mediterranean bartin,,with a maximal occurrence in Clprus (1 to 2/LOO>.
*** Linked to the x chromosome, this disease occura only in br>ys,with a frequency of 1,/3r500 (L/7 
.OOO for all births).
**** The occurrence of genetic immunodeficiencies is low.
Table 2z common chronic diseases with a multifactoriargenetic component
Disease Frequency in J.st
degree relatives
of affected persons
Peptic ulcer L/25 L/LORheumatoid arthritis L/SO L/2ADiabetes mellitus:insulin-dependent 1/500 L/gg
_insulin-independent L/SO L/LOIschaemic heart disease <65 yrs L/SO L/LOSevere manic-depressive psychosis L/LOO L/6Epilepsv (qrand nal) 1/200 1,/25
Frequencyin generalpopulation
r.2.3 TEC}TNOLOGIES FOR I,TAPPING GENES
fhere are different wayE of constructlng maps of the humangenome. rn its 
_moat_ simple form gene nappLng means aesJ.gning agen?^-t,o a epeclflc chromogome. The flrst cuch asaignment, rnlaeln 1911' was of the gene for colour-bllndnegs to the it chroinosome
and thts depended on the observatlon that males and not females
vrere affected. rn the aame wdy, several other x-linked genes
were discovered but aome fifty years passed before thedevelopment of new techniques allowed -the assignment of genes tothe other 22 pails of chromosomes. Even then there was no way oflocating genes whose product was unknown until, in the tli}a,
recombinant DNA technology provided a nelr approach. This
approach, called reverse genetics, depends on fir-st localizinel adisease gene to a particular chromosome by its association wlthgenetic markerg (identifiable regions on a chromosome) withinfamilies exhlbittng the dieeaEe. Thig procegs is expedited bythe availabillty of genettc linkage maps for each chromosome.
1.2.3.1 GENETIC TINKAGE !,TAPS
A genetic linkage map shows the distance between genes, andother genetic markersr on the basis of the frequency wftfr whichthey are inherited together. Genes that are close together on a
chromosome usually stay togetherr or linked, during the divisionof egg and sperrn cells, a process during which some parts of the
chromosomes recombine. The distance along genetic mapa,
represented by recombination frequency, is measured by how oflen
a particular gene ie inherlted separately from some marker and is
expressed in centimorgans. rf a gene and a marker on the same
chromosome are separated only 1t of the time, the distancebetween them is 1 centimorgan and this distance is on average 1mirrion base paira of DNA, although there will be nllordifferences from this depending upon which chromosome region is
under consLderation. Such observationg are made by studying the
cosegregation of genetic markers within familiee, and .,r"rylarge pedigrees are requlred to establlsh linkage relationlhipsbetween genetic markers with sufficient reriability. 16r
example' currently about 600 individuals in 40 large- familieshave been used to estabrish a linkage map to the 9 -centimorganlever. An improvement to between 1 and 5 centimorgans witr
necessitate an expansion of the total number of large familiea bya further 20.
Recombinant DNA technology introduced a nerr dimension to geneticIinkage ma_pping. Scientistg diecovered that restriction enzlzmesthe tools used to recognise a part,icurar, ghort DNA sequence
and cut it at that site 
- sometimes failed to cut the DNA of Eomepgggfe in the expected placee. As a result, fragments of adifferent length were produced and these variations wereinherited. Known as restriction fragment length polymorphisrns(RFLPE), they are used ag reference points along the genome
To identify RFLPs generated from very large pieces of DNA, it jls
necessary to use radioactively labelIed, single-stranded
aeguencea of DNA called DNA probes, which form bage pairs(hybrldlze) wlth complementary sequences in the RFIJP markers.
Some useful probes for RFLP mapping are fragments of genes,
others are complementary to a. new generation of markers,
"v:rriable number tandem repeats", which make use of the clusters
of repetitive DNA sequences found, in varying numbers, throughoutthe human genome.
L.2.3. 2 PHYSICAL I,TAPS
A physical map of the human genome shows the actual distance,
measured in base pairs of DNA, between genes or markers. Variouslow resolution methods of physical rnapping are known which aredependent upon dividing single human chromosomes into severalfragments. However, they locate onry very large pieces of DNA,into which either a few or thousands of genes might fit.Mechanisms for finding a gene of interest in long stretchert qf
DNA remain primitive.
New methods of separation of very large DNA fragments producet by
restriction enzymes which cut at very rare sites allow the
construction of long-range restriction f ragment maps, which frav'ea considerabry higher resolution and bridge the gap between thesingle gene ana the entire chromosome.
1.2.3.3 ORDERED CLONE LIBRARIES
Deveropment of- higher resolution physical maps is extre:nel.y
valuable in helping to locate genes of medical ihportance. Alsglfor physical mapping proJects, it is necessary to have accesrr t;orarge stocks of DNA and clone ribraries can provide such a
source.
cloning is n3ki1s multiple copies of a DNA fragment byincorporating it into a self-replicating molecule which-can uhe-nbe introduced into a host cell. Libraries are collections ofcloned DNA fragments from a conmon source. To construct, aphysical- ildP, the order of the cloned DNA fragments relative t,o
one another along the chromosomes must be known. The goal il; t.ocreate a comprete set, of overlapping clones, who6e order isknown, to cover the entire hurnan g-enome. once the phys Lcalrelationlhip between cloned fragments has been establishel, t5eirnucleotide sequence can be determined.
L.2.3.4 SEQUENCTNG
Th" ultimate phy_sical map wilr be the totar DNA seguence of thehuman genome. Although it is feasible to consider slquencing thegenome, to determine the totar sequence of 31000 million l>asepairs in a reasonable time would -require a very considerrrbleimprovement in existing techniques.
However, there is a case for first eequencing those regions ofthe genome which are believed to be clinically or scient.ificallyimportant. These would include chromosome regions in which
clinically important genes are either expressed i.e.transcribed into messenger ribonucleic acide (mRNAs) which are inturn transrated into protelna 
- or eerve some regulatoryfunctlon. One rnethod whlch has been proposed is first to iequence
DNA copies (cDNA) of cellular messenger RNA transcripts, with a
view to using that information to identify which genes are
expressed in the genome.
1.2.3.5 MANAGEMENT OF INFORUATION AI.ID I,IATERIALS
The production of higher resolution genetic and physical maps
will each generate an enormous amount of data; establishing the
correlations between them will generate even more. In both casesthere will also be a considerable requirement for thedistribution and collection of materials, e.g. probes, DNA
clones. The efficient management (and integration) of theinformation and of the handling of materials wilr be of primeimportance, and argues for the identification of a number of
central facilities each to become the centre of a research
network.
T.2,4 APPLICATIONS OF GENE I,IAPPING TN PREDICTIVE MEDICINE
1. 2.4.1 DIAGNOSTTC APPLICAUONS
Tests for genetic disorders are generarry used in prenataldiagnosis of abnormalities such as Down's slmdrome or in
screening the newborn for conditions amenable to treatment, such
as phenylketonuria. They are also used in screening adults(often from particular ethnic groups) for increased risks oftransmitting genetic disease to the next generation 
- forinstance, by identifying carriers of diseases such as sickle cell
anaemia, beta-thalassaemia, Tay-Sachs disease, etc.
Most. of the currently available tests are based not onidentifying the abnormal gene(s) but on detecting the geneproductl hence they are limited to some 2OO disorders where agene product or biochemical marker is known, a small number in
comparison to the 41200 known single gene defects. Otherlimitations to this approach lie in the inaccessibility of sometissues to sampling (eye, brain) and the probability that thedisease will have manif,ested itself perhaps imeversibly 
- bythe time that the genetic defect is detected. Tests whichdirectly detect the genetic lesion in the DNA overcome many ofthese linitations.
In the last five years, 400 or more genetic disorders have been
napped to a particular chromosome; of these, some 40 have beendefined in depth and include Huntington's disease (chorea),
cystic fibrosis and Duchenne muscular dystrophy. In each ofthese cases, a diagnosis can be made by a DNA-based test withoutknowing the gene's product or function. Further, the test canbe used for preclinical diagnosis of a disease of late onset
8
(such as Huntington's), for prenatal diagnosis and for detecbing
carrier status.
L.2.4.2 IDENTIFICATION OF GENES ASSOCTATED WITH DISEASE
Importantly' detection of the gene by reverse genetics can Leadtc our understanding its function and its rore in the patholoqy
of the disease concerned. Examples where this has alraady
occurred include Duchenne muscular dystrophy, chr,lni.cgranulomatous disease (a white blood cell disorder) and
retinoblastoma (a form of eye cancer). rt can be expected Ehatin the coming years many other disease genes will be isolatedl,including those involved in such disorders as colon carcinoma and
severe mental retardation. The availability of a hiryher
resolution genetic linkage map would sirnplify considerably th,eidentification of the genes involved in many conmon diseirses
whichr ds mentioned above, are caused by multiple gene defe,:ts.Computational methods exist which pennii the sirUpaititioningl ofgenetic rinkage data and identification of those g()nes
contributing to multiple gene detects.
This information, when combined with that derived ::rom
overlapping clone libraries, will permit the rapid isolation andstructural analysis of the genes concerned. Improved predicl:ion
of disease susceptibility will result. One of the most imporl:antdisease categories is that involving heart, and vascular disetrse.
L.2.4.3 GENE THERAPY
rt 
_ 
is hoped that eventuarly it may be possible to correct adefective gene by inserting normal DNA diiectly into a cell 
- aprocess known as gene therapy. This ultimately depends on thediscovery of safe methods of inserting the DNA ina of a meansi ofensuring that the DNA corrects the target defect witfuoutproducing any other adverse effects. Gene mapping will not laveany direct effect on the prospects for gene therapy but theknowledge- gained about the function of genes nav have anindirect benefit.
1..3 SOCIAI AND ETHICAL CONSIDERATTONS
rnformation about human genetic make-up will increase enormorrslyin the course of mapping the human genome; simpler, faster anh
19"" costly methods of screening foi genetic susceptibility trcdisease wirr be developed. This will piovide the polsibiritl oftherapeutic intervention to prevent the maniiestations ofdisease. As elenes are identified which are associated with anincreased risk of conmon diseases, such as heart disee.se,diabetes and arthritis, population screening will becomer ,ipossibility. rn western Europe, where there is a steadily ag€ringpopulation and an associated ever-increasing cost of healifr 6erelthe prospects both of cheaper testing and of earlier intervention
naking possible a decrease in morbidity are very attractive ores.
This enormous increase in genetic information does raise ethjcalquestions. fmprovements in diagnosis and risk prediction li'ilt
lnevitably precede the development of therapeutic remedies,creating a growing gap between diagnosis and treatment. Theinformation about an individual's genetic constitution wiII bemore precise, more detailed and more easily obtainedt it wilrbenefit indlviduals by Lnforming them about -health riskg but itcould also be used to their detriment by third parties such asemployers or insurance companies. Furthei ethical- considerations
will arise from the increased range of prenatal diagnoses whichwill become easily available pirents may seek td choose thesex of their children, for instance. These questions do notarise directly from the information which is c6llected but fronthe uses to which l-t is put. This inplies that, independently ofthe technical possibilities and beneiits offered by iruman genomeanarysis, it is vital that politicians and society as a -wholeconsider seriously the diremmas presented. Rspe-cts such aspersonal privacy, including the right of the individual to knowor not to know, must be weighed against general health careconsiderations.
Dialogue and information transfer on the social consequences andethicar aspects of such research will be organijed, in asystematic manner, with the various interested pariies.
There is a unanimous opinion that, also for ethical reasons,there must be 
- 
a reJection of any possibility of nodifying thegenetic constitution of human gern celrs, even for p-urerytherapeutic reasons; this topic will be excluded from- thi;European Community research progranme.
2. THE PREDTCTTvE lr{EDrcrNE pRocRAMME : Hu}!.NiI GENoME Al,tArysrs
The framework programme(l1 originally stated that the technicalcontent of the Predictive Medicine Programme would "mainly beoriented towards better knowledge of the human genome, immuiitytechniques (appricable to cancer, autoimfrune - diseaseslinfections), genetic engineering processes aiming at repairingDNA defects (g.g-. in congenital diseases of gene{ic originl anddevelopment of diagnostic test kits (e.g. for ArDs)". -since achoice has to be made, it seems appropriate to concentrate
endeavours on definition of the human genone.
The progranme will have these ains 3
1) To achieve a high-resorution genetic map (at 1 to 5centirnorgan level) of the human genome. This witt require anincrease from 40 to 50 in the number of large families cirrrentlygndgf- study in Europe, the extra 20, where possible, to bafamilies known to have a genetic modification of medicalinterest; the 
-setting up of a network of 10 to 15 Europeanlaboratories with both the interest in and the capabiritf of
working with material from these families; the estab-lishnenl of
I Framework Prograrune for Community Activities in the field ofResearch and Technological Development (198?-1991 ).OJ N" L 302, 24.10.1987, p. L-23.
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one or two centres which would provide DNA prepared from thefamilies to the members of the collaborating neCwork, and ,llso
maintain and distribute to them a collection of the necesiraryprobes; and consideration of the role of computing facili.;ie-sboth to enable participants to handre the coliection andreduction of these data and also to carry out the preparatiorr ofthe map.
2, To set up collections of ordered DNA clones either from theentire genome or from selected chromosomes. These ordered c.Lonelibraries, which might be produced in several centres, rvilrrequire the establishment of facilities for maintaining thestocks of cloned DNA fragments, and for distributing DNA - ::reeof charge to a network of European laboratories interestecl inmatching genetic material to these cloned fragments. A relirtedproJect could be the sequencing of cDNA clones isolirtedindependently and mapping them wittr- an ordered clone ribrary.
3) 
_To improve advanced genetic technologies, with the furl:heraim of sprelding them more -evenly among Eur-opean laboratoriesExamples are! production of new biochelnical ieagents (restricl:ion
enzlmes), procedures for labetling DNA probes, amplification ofgenes, vectorg for the transfer of human genes, methods ofcloning- long DN,A segrnents, development of -software to helpsequencing, devel,opment of- new 
- 
strategies for seguencing, an,lcreation of ove1lapping clone banks. rne best wa-y to s-uptrrortthis kind of 
.work- is by r,esearch contracts, with piiority !i.ve'nto collaborations between laboratories in dif ferent- uember S[e.te,sworking on a conunon subject, and also to those where there isparticipation by industrial laboratories. Communication betv,eenthe contracting laboratories will be so nanaged as to achieve i:tcolLaborative research network.
rn 
_ 
the process_ 
-of improving the genetic map and creating theordered clone libraries, due attention will- be given to thosechromosomes or chromosome regions known to contain the garr"uresponsible for- specific, genetic diseases, especially where thiswill optimize the use of existing fanily material. There is als<>a need to learn more about the location and function of thecurrentry unknown groups of genes involved in the multi_factorial disorders which form the maJor part of the burden ol:disease and where_ risk,,prediction is fartiicularly inportant. Apragmatic approach will be adopted io maintainlng a suitabrebalance between- these obJectivei, and to avoidinf unnecessaryoverlaps with other genome analysis progranmes.
A. European- pilot network for_ the prevention of one particulardisease taken as a model would be a valuable lo.i-tor medical.research in the 
-commu_nity, but this kind of pr6iect would neeclcareful preparation (both in choice of target and of methods),and the setting_ up-.of a rarge--scale programme would be premature.However, the predictive Medicine Frofrarnme could support Bheorganization of a collaborative action for the preparation o:E amore detailed 
_proJect. The development of an e*ien^sine Europ3annetwork night be an objective for Lhe forlow-up to this
tL
proqramme. Diseases of particular interest in this respect mightbe cystic fibrosis and phenylketonuria.
3. JUSTIFICATTON OF THE CONFORMITY OF THE PROGRAMME WITH THEOBJECTIVES AND I,TETHODS OF THE EUROPEAI{ COI,TMUNITY
3.1 CONFORIT{ITY WITH THE OBJECTIVES OF THE FRAUEWORK PROGRAilME OF
RESE.ARCH AI{D TECHNOLOGICAI, DEVELOP!{ENT
The Predictive Medicine Programme involves both technologicalresearch and training actions which will contribute to theachievement of many of the aims listed in the frameworkprogramme.
L) The activity "Quality of tife" includes the predictiveMedicine Prograrune in its "Health" line. This aspect is obvious,because the development of Predictive Medicine wilt decrease theprevalence of 
-many diseases which are very distressing for thepatient and his family, (incapacitating or painful chronicdiseases, often with a fatal outcome), as-welr ai being sociallyvery expensive for the Community.
2, 
_The goal "to promote scientific research and technologicaldevelopment at community level in order to strengthen thescientific alg technological basis of its industry"- is alsoexplicitly addr_essed by the proglramme, which aims to promote
advanced technorogies with q nrgh addeil value (e.g. DNA probes
fot diagnostic kits). lnformed estimates of the potentialEuropean market for DNA probes in the next decade suggesl that itis worth between 11000 and 21000 million ECU,/year
3) The goar of "participation of small and mediun-sizedenterprises" wirl also be met because most of the hightechnology enterprises which are able and willing to collaboraf,ein the progratnme are in this category.
4, The goal of "harmonious deveropment of the community with aview to strengthening its economic and eocial cohes-ion,' isespecially important in this field, where the state of scientificdevelopment differs widely between Member States. The provisionof- a large number of grants for intra-Community exctianges ofscientists, together with obtigatory trans-nationalcollaboration, will aim at promoting greater contact betweenindividual scientists and at technology transfer to the currentlyIess advanced laboratories in Member Slates.
For the future, a follow-up to this progr€unme night include thelaunching of a large-scale operation -concerning 6ne of the maindiseases of children (coordinated action including research,forecasting, prevention and treatment). Thie would ue the besi
way to convince Europeans in general that the creation of a
"Europe of health" is not merely a matter of public relations buta living reality.
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3.2 JUSTIFICATION OF THE SCIENTIFIC CONTENT OF THE PROGRAIIME:THE INTERNATIONAL CHALLENGE AND EUROPEAN SCIENTIFIC
COHESION
The Justification of the scientific content of the progroop€ wdsset out in the discussion of the scientific basis fbr predicrti.ueMrrdicine (cf . L.2r. rt is argued that the auiiiiv-io understandnonnal genetic- function, and hence to recognize t-he abnormal andtlen predict disease susceptibirity, rests on having access to a
"human gene dictionary", i.e. a detaiLed nap of it; position'fthe genes on the chromosomes. This involves- improvlment of thegenetic pap and the physical fiap, and the setting-u; of ordergdclone libraries of the-human genome in the snoit-term perhapsof either selected chromosome regions or genes. The totalsequencing of the 
_genome, which iJ the next logical step, -iisstirl a remote goal because existing techniqu"" .-t" too sror toalrow the sequencing of thg 31000'rnilriori u""" pairs ir. anacceptable time; a start could, however, be made oi, sequencingthe cDNA.
The Predictive Medicine Programme would thus enable Europer toaccept the challenge of remaining a vital internatirnarscientific force in human genetics
Ih" unllred states. 
-(us) report- "Mapping and sequencing the HrmanGenome"(z) is a wide-ranging pran rt{icri inc-rudel lt" g"""tic :napr,the physical rdp, an orclerea- pna crone riuiary ;;;r'urtimat,:l'.rsequencing. This impressive..and prestigious pl"gri**" it hasbeen compared 
.to the "Apol1o" pro jlcc iiJ trr" fierd oi ,p"." 
- hascaptured the imagination of miny scientists and politicians. ForJapan, the "Human Frontier scie-nce i"o!r.*rne" ii a-jroposar foran internationar research progranme :--n basic biorlqy and thedeveropmenr of associared -k"i tectrnoiogil".- ;;"1;" time ofwriting the content of this programrne has not been agreed, bu1: itmay weII include a commitmenl t5 human genome anarysis and/or thedevelopment of fast automatic DNA 
="q""i.i"g d"ipil;;;.
whatever view one may have of these projects, the Eurolreancommunity cannot remain indifferent. rurtirerfror"r'in -tne cas€r ofthe American 
- 
programme, active European participation isexplicitly sought. the predictive neaicine programme provides themeans for Europe- to participate in an exciting" p"":LJi in one ofthe most advanced sectors of biorogicar-iesearch.
3.3 RELATTON TO OTHER COMMUNTTY PROGRAMMES OF RESEARCH
within the framework programme, the predictive Medicine programmewilr be coordinated wlttr the following 
"G;iii;- communityprogranmes of research and technological deielo-p*""t1-in order toavoid overlap and to ensure coherente of research efforts:
2 "Mapping and- sequencing the Human Genome,,, Report of the Boardof Basic Biologlr commission on Life Sciences, National Researchcouncir. National Academy press pubrisher, washington D.c., 19gg.
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- The "Medlcal and Health Research" progranme 1982-1991, andespecially lts area r.1.4 "Early detectlon and diagnosis ofcancer" which is closely reLated to the genetic fieldthrough the topic of oncogenes. Both progrimmes forrq animportant part of the "Europe against cancer" programmer{3).
The "Advanced rnformatics in !{edicine in Europe' (ArM)progranme, e.specially its Action Line rr "strengtheningEurope's position in Medical and Biolnformatics (MBI) andhealth care", which courd give support for the development ofeffective communication and information processing wilnin theproposed networks.
The biotechnology programmes, especialry the progranme
BRTDGE, being prepared at present, with which it wourd becarefulry coordinated in respect of expression vectors, genetransfer ald, more generally, the genetic engineering of
animal and human cells.
The "Environmental protection" programme, especially its
research areas : "Environment and Human Health" and "GeneticEffects of Environmental Chemicals".
- The "Radiation protection" programme, especiarly its
mutagenesis area.
The "Stimu1ation"
"Biocommunication" area.
Programme, especially its
The programme wirl also benefit from slmergy with otheractivities of the community in the field bt rnformationTechnology and Telecommunication (IT&T).
3.4 PRECOMPETITIVE NATURE OF THE RESEARCH
The programme is one of basic precompetitive research. However,both new information and nerrr materials of potential commerciai
value wirr resurt. rt is generally agreed that arr the mappingand seguence information ihoutd Le ?reery avairable but thatassociated technological developments of instruments,
equipment, reagents or software should be protected in the
usual way by patents, copyright, etc.
3.5. UANAGEMENT AI{D EVAI,UATTON
The existing CGC on Medical and Health Research should deal withthe Predictive Medicine Programme and wiLl advise the Commissionin the manner defined in the Council decision creating CGCs. Theprogranme will be submitted to evaluation procedures in
accordance with the "Community plan of action relating to the
3 Decision of the Council and of the representatives of Mernberstates of 7 July 1986, concerning an action prograrnme of theEuropean Communities against cancer. O.J. N" C lB4, 23.7.97, p.19.
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evaluation of Community research and development activiti,ts"(4).The CGC may wish to obtain specialized advice and meet in
variable configurations; it may also wish to set up a l{orkingParty to advise the commission on the management of thePredictive Medicine Progranme.
4. IMPLEMENTATION AND FINANCIAL MEANS
lfter _the approval of the Medical and Health Research prorJramme,15 nillion Ecu remain on the sub-activity '1.1 Hearth" of th;framework progranme for the implementation of the pre<lictivgMedicine Programme. Four main chapters of expenditu::e ar3groposed, for two networks (human genetic map and orderecl clon=library of the human genome), research conlracts for uork in
advanced genetic technologies, and training grants. rn a<lditionthere would be overheads and staff expenses. The ind:lcativebudget distribution is:
CHAPTER MODE OF ACTION BUDG]TT(Miflion gCUl
fmprovement of the human Support to a network of 4.0genetic map centralized facilities
Ordered clone library
Research on advancedgenetic technologies:
e.g. reagents (restriction
enzymes), gene detection,gene
vectors, cloning, computer
software, cDNA cloning and
sequencing.
Grants (particularly post- Grantsdoctoral, 100 scientist-years)
Scientific management, including
evaluation
Staff
TOTAL 15.0
4.1. NETWORKS OF FACTLITIES
Progress with the human genetic map and the creation of crdereclcrone libraries of the human genome wilr be achievec. most;
ef f ectively by building on exisling l-aboratories throuqyh thercreation of networks. Efficient management, both of informatior,and of biological materials, will Ue of prime importance for 5ott.
As above
Research contracts 3.5
4.0
2.5
0.4:;
o. 5:;
4 communication to the council concerning e community plan ofaction relating to the evaluation of Cornmunity resiarch ,lnd,development activities for the years LggT to f-ggf.O.J. N" C L4, 20.L.87t p.5.
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actions, and it is proposed therefore to identify a centralIaboratory in each case to act as the focus for management, i.e.to become the centre of a network of laboratories.
Four million ECU will be used for the development of a European
network for the improvement of the human genetic map, and anotherfour milllon Ecu for setting up a network of laboratories
concerned with an ordered clone library of human DNA. These sums
amount to approximatery 10t of the sums suggested in the report
of the US Office of Technology Assessment as appropriate for theUS Human Genome Project. Although modestr dt least in the
exploratory phase of these activities, Europe's contribution tothe international effort will be a significant one.
4.2 RESEARCH CONTRACTS
The basic research on advanced genetic technologies in theprogramme will be funded through cost-shared and marginal cost
contracts with public and private institutions in the MemberStates. The contribution to research contract funding from theCommunity budget is estimated at 315001000 ECU. This figure isbased on an estimate of 20 research contracts on advancedtechnologies, of about 1501000 to 2001000 Ecu per contract (forthree years) according to the size of the proJect. ft correspondsto the expected response from European laboratories in the field.In the selection process, priority will be given to proposalsinvolving a number of Member states and/or participation byprivate enterprises. The management of conununication between the
various contracting laboratories will be a.first step towards the
establishment of a European network in molecular genetics.Arthough the sum involved in each contract may aeem smalr, theimpact wirl be amprified by the comprementarity of the progranmeto national research efforts. It should be noted that no singleEuropean country would be able to develop the complete range of
research facilities and networks described above.
4.3. TRAINING
An average estimate of the requirements for training in theperiod under consideration is about 100 scientist-years, i.e.2,5001000 ECU. frro aspects deserve special consideration:
(i) Steps must be taken to ensure that those Member States which
currently lack a capability in the techniques of modern
molecular genetics are given the opportunity to acquire it;
(ii) OnIy if there are very compelling reasons will scientists bepermitted to train outside the proposed European networks;in order to gmooth the path for the transfer of technology,
and for the return of the indivldual newly-trained
scientist, it is expected that 30 to 50t of such a
scientist's time will be spent introducing the newtechniques into his own laboratory setting.
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4. 4. SCIENTTFIC I{.ANAGEMENT
Budgetary provision of 450,000 ECU is considered necessary fc,rthe external scientific management of the progranme. 'this
assessment, based upon an analysis of current annual needs in
similar progranmes, covers the expenses of meeti:rgs,psrticipatlon ln aymposla, travel and gubsietence costs -oi
experts and commission staff, visits to laborato:liesparticipating in lhe pfogranrme (two visits to each contrac':inglaboratory, i.e. about 50 visits in the course of the programrne),
and the conveninq of six workshops during the same period. Frrndsare also included for the preparation of a follow-up to thepresent programme (studies and preparatory meetings) which m:-ghtinclude 
.rnlgg--alr.a the setting up, as mentioned pieviousry, c,f alarge network of research, forecasting, prevention and treatlrentfor one of the major genetic diseases of children.
The cost for scientific management amounts to 3t of the totalbudget requested for the progranme, incruding the cost of
evaluation.
4.5 COUMISSION STAFF
Expenditure of 550'000 ECU for a staff of two is considered
necessary for the execution of the progranme. This estinrateincludes new staff only, i.e. one offitiat of category A (93,000Ecu,/year ) and one of category c ( 37 , 000 ECU,zyear I ,- inf rai:ionbeing estimated at 4t per year; this estimate i-nctudes only theminimal requirements necessary for the management of theprogranme.
4.6 SUMMARY OF FTNANCIAL MEANS
(Million ECU)
Networks of facilities
Research contracts
TrainingScientific managementStaff
8.0
3.5
2.5
0.45
0.55
TqTAI, 15.00
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PROPOSAL FOR A COUNCIL DECISION
Adopting a research and technologicar development programme l-nthe field of health I Predictive DtedLcine !
Human Genome Analysis : (1989-1991)
THE COUNCIL OF THE EUROPEAN COMI{UNITIES
Having regard to the Treaty establishing the European EconomicCommunity, and in particular to Article 130 Q (2, thereof,
Having regard to the proposal from the Commission(1),
fn cooperation with the European ParliamenE(2r,
Having regard to the opinion of the Economic and socialCommittee(r),
Whereas Article 130 K of the Treaty stipulates that the frameworkprocJrarnme shall be implemented through specific progranmes
developed within .each activity;
whereas by its Decision of 28 September 1987(4) the Council has
adopted a framework prograrnme of community research andtechnological deveropment (1987-1991), in which it provided for
activities to be undertaken in the field of health;
whereas, fox the evaruation of each specific programme and the
selection of Community actions, the framework programme seta out
criteria among which is that of contributing to the strengthening
of the economic and social cohesion of the Conununity, consistent
with the pursuLt of scientl-fic and technical quality;
Whereas two successive pluriannual progranmes of research andtraining of the European Economic Community in the field of
lOJN"
2OJN"
3OJN"
4OJN' L 302, 24.10.87, p.1.
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biotechnologies{5), of which the second is still in progress,
have shown the possibility and usefulness of a Community acuionpromoting the utilization of modern biology for scientific andindustrial purposes;
Whereas the biotechnology progranme presently in progress ,loes
not include some fields of research important for human he,rlt.h
and the quality of life, fot the industrial development ofbiotechnologies with medical aims and for the control of the
increase of social and health expensesi
Whereas the f ramework progranme has foreseen in its acti'rit.y
"Quality of life" under the "Health" line 1.1, the "Initiatio:r c,f
new activities relating to the development of predic[iv.e
medicine" I
Whereasr ds a result, a specific research and technolog.Lcaldevelopment programme is necessary in the field of predic':ive
medicine and, in particular, that it is necessary to:
- develop the basic technologies concernLng the study of thehuman genomer &s a prerequisite to a large number ofdevelopments in biotechnology for health, and to ensure thedistribution of these technologies widely in Eurol>eanlaboratories, and
- improve the resolution of the human genetic map and to re:3inethe physical nap by the creation of ordered clone libraries, as
a basis for rocating genes of medical importance and for abetter general understanding of gene functioni
Whereas the carrying out of the above-mentioned goals require the
undertaking at Community level of actions aiming at:
filling some existing gaps in scientific and technolog:-cal
knowredge, gaps which prevent the full development of the
resources of modern biotechnologies in the medical field,
and
promoting, through concerted actions between private andpublic laboratories, European transnationar cooperal:ion
aimed at speeding up the implementation of technolo<yies
arready availabre while promoting European scientific ar:eas
which will encourage new approachea to be developed;
L
L
50J
OJ
NO
N"
375t 20.L2.1981, p.1i83, 25.3.1985, p.1.
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3Whereas the Scientlfic and Technical Research Connittee (CREST)
was consulted on the following meaaurea,
HAS ADOPTED THTS DECISTONT
Article 1
A_ specific research and technological developmentthe European Economic Conununity in the fieldMedicine : Human Genome Analysisr 
€ls defined inhereby adopted for a period of three years1 January 1989.
Article 2
The amount deemed necessary for the execution ofis 15 mitlion ECU, including expend,iture on apersons.
progranme for
of Predictive
the Annex, is
commencing on
the progranme
staff of two
1.
Article 3
Detailed rules for the implementation of the progranme are setout in the Annex.
Article 4
rn the second year of the progranme implementation, the
commission sharr undertake a review of the programme and itsharr report to the council and to the Europein parliament
on the results of this review, together, if hecessary, with
any proposals for modification or prolongation.
An evaruation of the results achieved shall be conducted byindependent experts and shalr be pubrished in the form of a
communication to the council and to the European parliament.
The above-mentioned reports shall be established having
regard to the obJectives and evaluation criteria set out i;the Annex to thig decision and in conformity with theprovisions of Article 2(2) of the framework progranme.
Article 5
The commission sharl be responsible for the execution of theprogranme and shall be assisted in its imprementation by theI{anagement and Coordination Advisory Conunittee (CGC) onMedical and Health 
-Research, set up by Decision84 / 338 / Euratom/ECSC,/EEC ( o ) .
5 OJ N" L L77, 4.7.1984, 9.25
2.
3.
1.
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2. The contracta entered into by the Commigsion shall ragulate
the rights and obllgatlons of each party, and in parLicular
the methods of disseminating, protecting and exploit:Lng the
research results.
Article 6
In conformity with Article 130N of the EEC Treaty, the Comnissionis authorized to negotiate agreements with non-member StaEes andinternational organizations, particularly with non-member States
taking part in European cooperation in the field of sciantific
and technical research (COST) and with countries which have
concluded scientific and technical frarnework cooparation
agreements with the Community, with a view to associatirrg themfully or partially with the programme.
Article 7
This Decision is addressed to the Member States.
Done at 1988
For the C,)ultcil r
The Presirlent.
2L
5ANNEX
for a speclfic research progratnme Ln the field of health 3Predictive Medicine : Human Genome Analysis
1. OBJECTIVES
Use_ and improvement of new biotechnologies for risk-forecasting,
early diagnosis, prevention, prognosis and treatment of somehuman diseases, and for a better understanding of the mechanisms
of heredity.
2. CONTENT
Precompetitive Community research , setting up and reinforcementof networks of European laboratories, and tiaining intended toallow the use of modern biotechnologies for the improvement of
risk-forecasting, early diagnosis, prevention, prognosis andtreatment of some human diseases (in particular hereditarydiseases and cancers).
2.L TMPROVEI'IENT OF THE GENETIC U.AP OF I{AN
Establishment of a Europe-based network, with a worldwide extent,for the correction of the DNA of large families, in order toprovide free of charge to research scientists we1l-characterizedgenetic material and a set of probes to determine the location ofthe relative positions of genes on the chromosomes. possibleprovision of computer facilities to handle the data.
2.2 sETTrNc uP oF AN ORDERED cLoNE TJTBRARY oF HTMAN DNA
Settilg up of a European network of laboratories working onestablishing overlapping croned libraries, and support forlinited sequencing of cDNA.
2.3 RESEARCH ON THE IMPROVEMENT OF ADVAI{CED GENETTC TECHNOLOGTES
New biochemical reagents (restriction enzymes, etc. ).Improvement of methods for the detection and localization ofgenetic markers (techniques for labelling DNA probes,
amprification of genes, etc. ). Development of new vectors forthe cloning of rarge DNA fragments and of procedures for thetransfection of chromosomes. Development of model systems forthe reproducible and stable expression of medically importantgenes both in vivo and in vitro. Development of nevr computer
software for the collection and manipulation of data from genorne
sequencing and mapping.
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2.4 TRAINING
Settlng up a tralning progranme to agsist with the techno.Logy
transfer of molecular genetics methods to Member States in which
these techniques are currently underdeveloped and, in particu.Lar,the transfer of techniques into the clinical field.
3. IMPLEMENTATION
The programme shall be implemented through cost-shared or
narginal cost contracts, support to centralized facilities and
networks, training contracts, training grants, courtres,
consultations with national experts, organization of study-g::oup
meetings, participation in seminars and symposia, andpublications.
The Commission participation may range from about 50t in the (..ase
of cost-shared contracts and may reach 100t in other cases.
Participants may be research institutions, universities, pri'rate
enterprises, or combinations of them, Iocated in Member Stater; orin the third countries referred to in Article 6.
ProJects must be carried out by participants from more than one
country' and include at least one participant from one MernberState.
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EVALUATION CRITERIA
The community pran of action rerating to Ehe evaruation ofComnunity research and development programmes(/) states that the
milestones and obJectivee for each research progranme have to be
set out in verifiable and, where appropriate, quantitative form.
These are listed below:
1. The long-term obJective of this progranme is to contribute tothe fight against human diseases arising from genetic
variation (including genetic diseases sensu stricto and many
conmon diseases with a genetic component, such as heartdisease and cancer), through forecasting the risk, earrydiagnosis, prevention, irnprovement of prognosis and,
urtimately, therapy. The commission proposes to achieve this
obJective by :
- the management of a network of laboratories set up aroundEuropean facilities for (a) the improvement of the humangenetic map and (b) the setting up of ordered clone libraries
of human DNA, either of the comprete genome or of selected
chromosomes, together with cDNA sequencing;
- the launching of a progranme of precompetitive research
contracts on advanced genetic technology;
- 
the setting up of a programme of training to increase thedistribution of modern genetic technologies in Europe, and toimprove technologicar know-how in European laboratories.
2. The primary short-term obJective is that the programme should
succeed in establishing the above-mentioned European networks
of laboratories in the field of:
- the human genetic map
- ordered clone ribraries of human DNA and cDNA sequencing
- advanced genetic technologies.
These obJectives should be verifiable in L990*1991.
3. Particular obJectives to be attained within three years ofthe progranme implementation are as followsc
3.1 Concerning the human genetic maps
- the present total of 40 well-studied large families which formthe basis for the genetic map shourd be increased to 60families;
- 
genetic materiar from these families, and DNA probes, should be
made available free of charge to interested Europeanlaboratories;
24
7 OJ N" C L4, 20.L.87 | p.5
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- a central facility should be set
establish an improved genetic map
1evel;
up to pool the resultri and
at the 1 to 5 centimr)rgan
3.2 The strategies for setting up ordered clone libraries ofhuman DNA shourd be compared and an approach def.Lned;facilities for maintaining the stocks of ctoneO DNA fragnentsshould be established and the available clones dispir:chedfree of charge to interested European laboratories.
3.3 Substantial improvements should be obtained in the foll<>wing
advanced genetic technologies:
- New reagents, such as restriction enzymes,
- Methodology for croning large DNA fragments and for thetransfection of chromosomes,
- Gene vectors adapted to human cells in vitro,
- Irlethodglogy for the detection of a particular gene in a celr(exampres : how to make the use of DNA pr5bes and geneamplification easier ),
- Locarization-, croning and sequencing of new gcrnes,especially those which are disease-relate-d,
- New, computer software for the storage, collation arndanalysis of DNA sequence data.
4. rn addition, th" programme should ensure that the follcwirrggeneral criteria are mets
4.1 That throughout the execution of the progranme, the proJeclgsshould have taken- adequately into consideration the .oipi**ethicar aspects of human genetics, avoiding any manipurationof human ge:rn celrs, and any risk to the eniriro-trment.
4.2 That medica-r deveropments are actually or potentiar-Lyfacilitated by the results obtained.
4'3 That potential opportunities for commercial developments areobtained.
4'4 That the overall technological level of the participatirrgEuropean laboratories has been increased.
4.5 Taking account of the results of community, national orprivate sector research activities in hurnari 'genetics, ttreevaluation panel shall consider whether tha predictil,eMedicine Programme has contributed to the appfi-ation of theresults of the said activities in regions t-f th; Comrnunityother than those in which the research was conducted.
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FINAIiICIAL RECORD
PREDICTIVE I{EDTCINE PROGRAMME
}. RELEVANT BUDGET HEADING
- Post: Line 73L2
2,
Title: Specific research andprogramme in the field of health
LEGAL BASIS
technological development
- Predictive Medicine.
Article 130 of the Treaty,Council Decision.
3. DESCRIPTION OF ACTION AIiID OBJECTTVES
3.1 Description
community programme (1 January 1989-31 December 1991) for
research and training in predictive medicine, carried out by
means of implementation of laboratory networks, research andtraining contracts, consurtancies bt experts, orltanization
of workshops, contribution to slzmposia, and studies.
3.2 Oblectives
The obJectives of the programme are the following: Community
research and technological development in molecular geneticsto achieve a better understanding of genetic disease andhence improve the prospects for diagnosis and therapy.
4. JUSTIFICATION OF ACTION
The choice of predictive medicine as one of the targets forConmunity efforts in health matters takes into account three
elements:
- The priority to be gi-ven to advanced technologies, andparticularly to modern biotechnologies, the importance of
which for European economic development is an indisputablefact.
- 
The seriousness of the hurnan and social aspects of somediseases in particular the common diseases which resultfrom a combination of genetic factors interacting with the
environment.
- 
The economic importance of health expenditure, which is
constantly increasing in Europe and is a serious problemfor the governments involved.
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These three erements come together in the definition of a
research action programme in the field of biotechnologies tr> be
applied to predictive medicine: this field covera diselses oEten
of long duration, socially expensive and very distressing i.nhutan terms, where it is now possibte to anticipate their elrrlydetection. This will lead to their prevention and eventuaLtreatrnent, through using the resources of modern biotechnology
while stimulating European industry.
5. FINANCIAI, INCIDENCE OF ACTION ON EXPENDITURES
(including costs for staff and expenses for administra'tive
and teehnical management)
Million EtlU
5.1. Total cost over the whore of the expected duration 30
5.2.
5. 3.
Staff
Adninistration
Contracts andtraining grants
Total
5.3.2. Pavments
Staff
Administration
Contracts andtraining grants
Total
1989 1990 1991
0.14 0.20 0.210.20 0 .L2 0.13
1.66 6.68 5.66
2.00 7.00
Participation in funding:
- From the Community budget
- From national budgets and other sectors
at national level
15
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Murtiannuar schedule of commitment Appropriations andPayments from the Community budget
5.3. 1. Commitment Approoriations
TOTAL
0.55
0.45
14.00
15.006 .00
L9921989 1990 1991
0.14 0.20 0.210.20 0.L2 0.1.3
0 .46 2.98 5 . 36
1993
4.10 1.10
TOTAI,
0.55
0.45
14.00
0.80 3.30 5.70 4.10 1.10 15.00
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5.3.3. Methods of calculation
5.3.3.1. Staff expenditure
The staff requirements for the S.mplementation of this programme
are !
I category A staff, (*)
1 category C staff. (*)
The above-mentioned calculation of staff expenses is based on thefollowing annual figures for 1989-1991: s3r-o0o Ecu for an A post,371000 Ecu for a c_ post, infration being arlowed for at 4{ peryear. Expenditure for missions of Commisiion staff, for nationalexperts and auxiliary staff are also included under this heading.
5.3.3.2.
This heading covers the expenses of meetings, participation insYmposia, and travel and subsistence costs of- exp-erts, as well asthe publication and dissemination of results Lnd information,together with the cost of scientific and technical assistancewhenever it proves neceasary for the imprementation of theprogramne.
5.3.3.3.
The budget foreseen for contracts and training grants (L4 millionEcU) should 
_ 
permit the conclusion of reseaich and developmentcontracts (for a total amount of 11.5 milrion Ecu) with anaverage length of 2.5 years (the duration of the progranme beingthree years, but allowance being made for the perila 5t the calr{ot proposals and the period of adrninistrativ6 negotiation), andfor a variable amount according to the subJect of Lhe research.
with regard to 
- 
train_ing 
_ 
contracta and the short-term t,raininggrants, the method of calculation is based upon an average costof 291000 Ecu per year per scientist. rC is foreseen thatapproximately 20-22 training contracts and l0-15 short-termtraining grants wirl be allocated each year. The total amountdevoted to training actions will be 2.s nittion Ecu.
6. Financino of expenditure
The appropriations required to cover the Community's contributionto-this proJect are to be entered in the corfrnunity,s futurebudgets.
('f ) 6 months in 1989.
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7. Tvpe of Control
Administrative control by the Director-General forFinancial Control (DG XX) as regards brrdget
implementation, and by the Contracts Division of DG XII. ,
Scientific Control by the responsible officialr; in
DG XfI assisted by the CGC. t'
Audit by the Court of Auditors in accordance witt, theprovisions of the Treaty.
Evaluation in accordance with the Community plan of
action' See also the Evaluation Criteria in the i\nnex
to the Council Decision.
8. Financial Record
Summarv
Action : Research and technical development inPredictive Medicine.
Expenses Staff(MillionECU) A B C(Number of posts) r
TOTALg 15. 1 
- 
1,
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STATEMENT ON THE IMPACT ON S}ALL AIID T{EDIW-SIZED ENTERPRTSES,
COMPETITIVENESS AI{D EMPLOYMENT
Artlough no! primarily aimed either at the support of smarr and
medium-sized enterprises or at the solution of the problems ofindustrial competitiveness and employment, the predictiveMedi-cine Programme should nevertheless have some positive resultsin this respect:
1. The improvement in advanced genetic technoloqies shouldlead to worthwhile developmentss
The production of nelr reagents (such as restriction
enzfzmes) could provide a good opportunity for the
commercialization of high added value substances.
The obtaining of new DNA probes, and the
simplification of their practical use, should permitthe deveropment of new diagnostic kits. rnformar
estimates of the potentiar market for DNA probes inthe next decade in Europe indicate that it is worthbetween 1r000 and 2r000 million ECU/year.
New techniques for gene amplification might arso give
rise to development of commerciat kits.
2- llost of the high technology enterprises which are bothable alq wilring to corlaborate berong to the category
of smarl and medium-sized enterprises, and shourd bA
stimulated by the implementation of the progranme.
3. fn the longer term, the Predictive Medicine progranme
can be considered as a valuable contribution to an
arternative approach to the problem of steadilyincreasing health expenditure in European society, andthis should urtimatery result in an increase in the
competitiveness of the Community.
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